14 October 2022

Physiomics plc

("Physiomics") or ("the Company")

Conference attendance

Physiomics to attend BioEurope

Physiomics plc (AIM: PYC), a provider of technology-based solutions to predict the effects of treatment regimens for cancer and other therapeutic drugs for the biopharma industry, is pleased to announce that it is attending the #BIOEurope conference in person in Leipzig, Germany on 24-26 October 2022.

BIOEurope is one of the world's premier biotech partnering conferences and is expected to host over 4,000 executives from over 2,200 companies at this year's event. 

Physiomics Head of Business Development, Hayley Close, will be attending the conference to meet with prospective clients, in particular those with assets between late discovery and early clinical development. Companies interested in meeting Physiomics at the conference should reach out to us via the conference partnering system or email Hayley directly at hclose@physiomics.co.uk.

Enquiries:

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company's Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics' technologies have been confirmed by over 90 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.